BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 29885652)

  • 1. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM.
    Li M; Chen X; Chen L; Chen K; Zhou J; Song J
    J Transl Med; 2018 Jun; 16(1):161. PubMed ID: 29885652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
    Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
    J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.
    Sonsöz MR; Yilmaz M; Cevik E; Orta H; Bilge AK; Elitok A; Onur I; Komurcu-Bayrak E
    Heart Lung Circ; 2022 Feb; 31(2):199-206. PubMed ID: 34088630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy.
    Puckelwartz MJ; Pesce LL; Dellefave-Castillo LM; Wheeler MT; Pottinger TD; Robinson AC; Kearns SD; Gacita AM; Schoppen ZJ; Pan W; Kim G; Wilcox JE; Anderson AS; Ashley EA; Day SM; Cappola T; Dorn GW; McNally EM
    J Am Heart Assoc; 2021 Apr; 10(7):e019944. PubMed ID: 33764162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Fang L; Ellims AH; Moore XL; White DA; Taylor AJ; Chin-Dusting J; Dart AM
    J Transl Med; 2015 Sep; 13():314. PubMed ID: 26404540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy.
    Calderon-Dominguez M; Belmonte T; Quezada-Feijoo M; Ramos M; Calderon-Dominguez J; Campuzano O; Mangas A; Toro R
    Sci Rep; 2021 Apr; 11(1):7517. PubMed ID: 33824379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of circulating miRNAs as a novel tool to assess BAG3-associated familial dilated cardiomyopathy.
    Zaragoza C; Saura M; Hernández I; Ramirez-Carracedo R; García-García F; Zamorano JL; Mangas A; Toro R
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30792263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy.
    Matoh F; Satoh H; Shiraki K; Saitoh T; Urushida T; Katoh H; Takehara Y; Sakahara H; Hayashi H
    J Card Fail; 2007 Jun; 13(5):372-9. PubMed ID: 17602984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy.
    Toro R; Blasco-Turrión S; Morales-Ponce FJ; Gonzalez P; Martínez-Camblor P; López-Granados A; Brugada R; Campuzano O; Pérez-Serra A; Rosa Longobardo F; Mangas A; Llorente-Cortes V; de Gonzalo-Calvo D
    J Mol Med (Berl); 2018 Aug; 96(8):845-856. PubMed ID: 30008018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy.
    Lakdawala NK; Thune JJ; Colan SD; Cirino AL; Farrohi F; Rivero J; McDonough B; Sparks E; Orav EJ; Seidman JG; Seidman CE; Ho CY
    Circ Cardiovasc Genet; 2012 Oct; 5(5):503-10. PubMed ID: 22949430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
    Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
    Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling.
    Zalivina I; Barwari T; Yin X; Langley SR; Barallobre-Barreiro J; Wakimoto H; Zampetaki A; Mayr M; Avkiran M; Eminaga S
    J Mol Cell Cardiol Plus; 2023 Dec; 6():100056. PubMed ID: 38143961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the peripheral blood levels of circulating microRNAs with both recurrent miscarriage and the outcomes of embryo transfer in an in vitro fertilization process.
    Yang Q; Gu WW; Gu Y; Yan NN; Mao YY; Zhen XX; Wang JM; Yang J; Shi HJ; Zhang X; Wang J
    J Transl Med; 2018 Jul; 16(1):186. PubMed ID: 29973278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of miR-208b improves cardiac function in titin-based dilated cardiomyopathy.
    Zhou Q; Schötterl S; Backes D; Brunner E; Hahn JK; Ionesi E; Aidery P; Sticht C; Labeit S; Kandolf R; Gawaz M; Gramlich M
    Int J Cardiol; 2017 Mar; 230():634-641. PubMed ID: 28065693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Exosomal MiR-92b-5p as a Potential Biomarker for Acute Heart Failure Caused by Dilated Cardiomyopathy.
    Wu T; Chen Y; Du Y; Tao J; Zhou Z; Yang Z
    Cell Physiol Biochem; 2018; 46(5):1939-1950. PubMed ID: 29719295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-Regulated Pathways for Hypertrophic Cardiomyopathy: Network-Based Approach to Insight into Pathogenesis.
    Osmak G; Baulina N; Kiselev I; Favorova O
    Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.
    Hamada T; Kubo T; Kitaoka H; Hirota T; Hoshikawa E; Hayato K; Shimizu Y; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Takata J; Doi YL
    Clin Cardiol; 2010 Jul; 33(7):E24-8. PubMed ID: 20641106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Genetic Determination of the Differentiation Between Ischemic Dilated Cardiomyopathy and Idiopathic Dilated Cardiomyopathy.
    Onrat ST; Onrat E; Ercan Onay E; Yalım Z; Avşar A
    Genet Test Mol Biomarkers; 2018 Nov; 22(11):644-651. PubMed ID: 30346833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cardiac MicroRNAs safeguard against dilated cardiomyopathy.
    Cheng X; Jian D; Xing J; Liu C; Liu Y; Cui C; Li Z; Wang S; Li R; Ma X; Wang Y; Gu X; Ge Z; Tang H; Liu L
    Clin Transl Med; 2023 May; 13(5):e1258. PubMed ID: 37138538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.
    Vegter EL; Ovchinnikova ES; Silljé HHW; Meems LMG; van der Pol A; van der Velde AR; Berezikov E; Voors AA; de Boer RA; van der Meer P
    PLoS One; 2017; 12(5):e0177242. PubMed ID: 28475616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.